The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways
Open accessAbstract
The intestinal microbiota is well known to have multiple benefits on human health, including cancer prevention and treatment. The effects are partially mediated by microbiota-produced short chain fatty acids (SCFAs) such as butyrate, propionate and acetate. The anti-cancer effect of butyrate has been demonstrated in cancer cell cultures and animal models of cancer. Butyrate, as a signaling molecule, has effects on multiple signaling pathways. The most studied effect is its inhibition on histone deacetylase (HDAC), which leads to alterations of several important oncogenic signaling pathways such as JAK2/STAT3, VEGF. Butyrate can interfere with both mitochondrial apoptotic and extrinsic apoptotic pathways. In addition, butyrate also reduces gut inflammation by promoting T-regulatory cell differentiation with decreased activities of the NF-κB and STAT3 pathways. Through PKC and Wnt pathways, butyrate increases cancer cell differentiation. Furthermore, butyrate regulates oncogenic signaling molecules through microRNAs and methylation. Therefore, butyrate has the potential to be incorporated into cancer prevention and treatment regimens. In this review we summarize recent progress in butyrate research and discuss the future development of butyrate as an anti-cancer agent with emphasis on its effects on oncogenic signaling pathways. The low bioavailability of butyrate is a problem, which precludes clinical application. The disadvantage of butyrate for medicinal applications may be overcome by several approaches including nano-delivery, analogue development and combination use with other anti-cancer agents or phytochemicals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“(2018) found that Ruminococcaceae family was richer in melanoma patients responding to anti-PD-1 immunotherapy [18].”
BackgroundRegulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 3×
“The role of the commensal bacteria in cancer immunotherapy was further confirmed by the experiment in mice which showed that fecal microbiome transplantation (FMT) from responding patients to germ-free mice increased the responses to anti-PD-L1 treatment [17].”
BackgroundVEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 3×
“In addition, overexpression of GPR109a in a cultured cancer cell line with addition of its activator caused apoptosis [101].”
BackgroundRegulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 1×
“Gopalakrishnan et al. (2018) found that Ruminococcaceae family was richer in melanoma patients responding to anti-PD-1 immunotherapy [18].”
BackgroundConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145
Protein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
Polakis, P. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008052 · Cited by 847
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Waldecker, M., Kautenburger, T., Daumann, H., Busch, C., & Schrenk, D. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.08.002 · Cited by 615 · cited 1×
“Butyrate has been demonstrated to be the metabolite that exhibits the strongest preventive and therapeutic effects on cancer [24].”
BackgroundChen, G., Ran, X., Li, B., Li, Y., He, D., Huang, B., Fu, S., Liu, J., & Wang, W. (2018) · eBioMedicine · doi:10.1016/j.ebiom.2018.03.030 · Cited by 580 · cited 1×
“In a mouse model with colitis stimulated by 2,3,6-trinitrobenzene sulfonic acid (TNBS), butyrate reduced inflammation through inactivation of Akt and its downstream NF-κB signaling pathways [77].”
BackgroundImpact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation
Bach Knudsen, K. E., Lærke, H. N., Hedemann, M. S., Nielsen, T. S., Ingerslev, A. K., Gundelund Nielsen, D. S., Theil, P. K., Purup, S., Hald, S., Schioldan, A. G., et al. (2018) · Nutrients · doi:10.3390/nu10101499 · Cited by 572
Flores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z. Q., Harper, J. W., Elledge, S. J., O'Donnell, M., & Hurwitz, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8655 · Cited by 416
The human microbiome in evolution
Davenport, E. R., Sanders, J. G., Song, S. J., Amato, K. R., Clark, A. G., & Knight, R. (2017) · BMC Biology · doi:10.1186/s12915-017-0454-7 · Cited by 393
Probiotic Strain Lactobacillus casei BL23 Prevents Colitis‐Associated Colorectal Cancer
Jacouton, E., Chain, F., Sokol, H., Langella, P., & Bermúdez-Humarán, L. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01553 · Cited by 249 · cited 1×
“Dysbiosis, which is caused by the dysregulation of the microbiota, can increase chronic inflammation states and decrease immune responses, leading to an increased cancer incidence [7,8].”
BackgroundButyrate-Induced Differentiation of Colon Cancer Cells Is PKC and JNK Dependent
Orchel, A., Dzierżewicz, Z., Parfiniewicz, B., Weglarz, L., & Wilczok, T. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2463-6 · Cited by 95 · cited 4×
“It has been shown in HT-29 and HCT8 cells, GPR3 activation caused cell cycle arrest and increased p21 levels and decreased levels of cyclin D3 and cyclin-dependent kinases (CDKs) 1 and 2 [108].”
BackgroundInfluentialFecal microbiota transplantation: a practical update for the infectious disease specialist
Moore, T., Rodriguez, A., & Bakken, J. S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit950 · Cited by 69
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers · doi:10.3390/cancers10040095 · Cited by 51
Cited by
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Chen, J., & Vitetta, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155214 · Cited by 352
Self-citationCurcumin and colorectal cancer: An update and current perspective on this natural medicine
Weng, W., & Goel, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.011 · Cited by 287
Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01965-2 · Cited by 256
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Metadata
- Authors
- Chen, J., Zhao, K.-N., & Vitetta, L.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2019-05-07
- Volume
- 11
- Issue
- 5
- Pages
- 1026
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2944064567
- Cited by
- 198
- References
- 28
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.